Skip to main content
. Author manuscript; available in PMC: 2020 Oct 13.
Published in final edited form as: Am J Hematol. 2018 Sep 26;93(11):1394–1401. doi: 10.1002/ajh.25261

Table 5:

Next therapy following ibrutinib in patients with del(17p13) or age <65 years

Post Ibr Therapy del(17p13) present Age <65 years
Alternate KI 2 (9%) 2 (10%)
Anti-CD20 antibody 7 (32%) 4 (19%)
BR or FCR 3 (14%)
Anthracycline-based regimen 3 (14%) 1 (5%)
Venetoclax 5 (23%) 5 (24%)
SCT / CAR-T 2 (9%) 4 (19%)
Other 1 (4.5%) 2 (10%)